98%
921
2 minutes
20
Objective: To study the results, re-donation situation and characteristics of single-reagent reactive blood donors who were put into the reentry strategy in Wuhan area, explore the rationality and effectiveness of the current reentry strategy, and provide data support for the improvement of the reentry process of blood donors.
Methods: From January 2020 to December 2023, blood donors who conform the reentry criteria and voluntarily applied for returning to Wuhan Blood Center were tested and the results were analyzed. According to the reentry strategy, serological testing and nucleic acid testing were carried out in parallel, serological testing was performed by ELISA with reagents from two different manufacturers, and the primary reactive samples were tested by double-well retest, and HBV/HCV/HIV nucleic acid detection was performed by RT-PCR with an individual donor test mode. Supplementary HBcAb testing was applied for HBV single reagent reactivity by chemiluminescence method. Supplementary TP-WB testing was applied for returning blood donors with repeated TP single reagent reactivity. If returning blood donors with HIV single reagent reactivity were repeated single reagent reactivity, the samples were sent to local CDC for confirmatory test.
Results: 7 098 blood donors were qualified for reentry, 716 donors voluntarily applied for reentry, 436 donors successfully reentry, 251 donors entered the next round, 29 donors could not reentry. The reentry rates for the past four years were 66.67%(42/63), 54.73%(81/148), 60.71%(136/224) and 62.99%(177/281), respectively. Up to December 31, 2023, 275 donors donated blood again, and the donation rates for past four years were 76.19%(32/42), 72.84%(59/81), 61.76%(84/136) and 56.50%(100/177), respectively. After donating blood, 31 donors were disqualified again by blood screening and subjected to permanent deferral. The results of returning to the team had statistical differences in reentry items, educational level, age, and marriage( < 0.05).
Conclusion: The current reentry strategy adopted by the blood donation and supply institution can effectively retain part of blood donors, reduce the negative emotions of blood donors and increase blood resources.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.033 | DOI Listing |
Cell Tissue Bank
September 2025
Eurofins Donor & Product Testing, LLC, Centennial, CO, USA.
In the United States, the use of Food & Drug Administration (FDA)-licensed, approved, or cleared tests is required for infectious disease screening and determining the eligibility of deceased donors for all Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). With the discontinuation of two manual enzyme-linked immunoassay (EIA) tests, automated Chemiluminescent Microparticle Immunoassay (CMIA) technology was introduced as the primary alternative. This study compares serologic reactivity rates between manual EIA and automated CMIA methods.
View Article and Find Full Text PDFSAGE Open Nurs
September 2025
Faculty of Health Professions, Al-Quds University, Abu Dies, Palestine.
Introduction: Blood supply shortages remain a pressing global health issue, particularly in resource-limited regions. The West Bank region in Palestine, characterized by frequent conflicts and instability, faces additional challenges due to its fragile healthcare system, where a substantial proportion of blood donations still relies on family-replacement donors rather than voluntary donations.
Objective: This study examines changes in knowledge, attitudes, and practices (KAP) related to blood donation among Palestinians from 2022 to 2025, aiming to guide strategies for a sustainable voluntary donation system.
Prev Med Rep
October 2025
Planning Funding and Outcomes, Te Whatu Ora Health, New Zealand.
Objective: To investigate prevalence of Human T-cell Lymphotropic Virus type 1 or 2 (HTLV-1/2) using the New Zealand Blood Service (NZBS) data, to inform whether further HTLV-1/2 prevalence study may be required, in the context of drivers of the inequities in lung cancer for Māori (the Indigenous population).
Methods: This observational cross-sectional study used the NZBS data of all blood donors nationwide (01/01/2001-30/06/2024). Prevalence overall and by ethnicity was calculated as the number of confirmed HTLV-1/2 positive cases per 10,000 donors.
Front Pharmacol
August 2025
Department of Pharmacy, Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh, Malaysia.
Sickle cell disease (SCD) is an inherited blood disorder marked by the production of abnormal hemoglobin, leading to the distortion-or sickling-of red blood cells. The SCD arises from a single-point mutation that substitutes glutamic acid with valine at the sixth codon of the β-globin chain in hemoglobin. This substitution promotes deoxyhemoglobin aggregation, elevating red blood cell stiffness, and triggering vaso-occlusive and hemolytic repercussions.
View Article and Find Full Text PDFFront Immunol
September 2025
Medicine 1 Unit, Ca' Foncello University Hospital, Treviso, Italy.
Background: Anti-integrin αvβ6 IgG autoantibodies showed good sensitivity and optimal specificity in ulcerative colitis (UC) compared to controls. We aim at confirming the diagnostic accuracy of anti-integrin αvβ6 autoantibodies in an Italian multicentric cohort.
Methods: This observational multicentric study included adult and pediatric patients with inflammatory bowel disease and controls.